Lipid based Pharma Excipients Market Size, Share, Trend, Revenue Report 2026 to 2035
Share With :
Lipid based Pharma Excipients Market Size is valued at USD 1.03 Bn in 2025 and is predicted to reach USD 1.96 Bn by the year 2035 at a 7.0% CAGR during the forecast period for 2026 to 2035.
Lipid based Pharma Excipients Market Size, Share & Trends Analysis Distribution by Product Type (Fats, Oils, Phospholipids, Waxes, and Others), Formulation (Injectables, Enteral, and Topical), Functionality (Solubilizers & Wetting Agents, Penetration Enhancers, & Solvents, Structuring Agents & Lubricants, Emollients, Emulsifiers & Surfactants, and Others), End-user (Pharma & Biotech Companies, Contract Research Organizations (CROs) & Contract Development and Manufacturing Organizations (CDMOs), Contract Manufacturing Organizations (CMOs), and Academic & Research Institutes), and Segment Forecasts, 2026 to 2035
Lipid based Pharma Excipients Market Key Takeaways:
|
Specialized lipid materials called lipid-based pharma excipients are used in drug formulation to increase the solubility, stability, and bioavailability of active pharmaceutical ingredients (APIs). These excipients, which are crucial for creating oral, topical, and parenteral drug delivery systems, include oils, fats, phospholipids, surfactants, and other lipid derivatives. To increase therapeutic efficacy and patient adherence, they are frequently utilized in solid lipid nanoparticles, liposomes, self-emulsifying drug delivery systems (SEDDS), and other cutting-edge drug delivery technologies. Strict regulatory requirements are met in the production of lipid-based pharma excipients, guaranteeing their quality, safety, and uniformity in pharmaceutical applications. The lipid-based pharma excipients market is growing because pharmaceutical companies are dealing with more and more poorly water-soluble active pharmaceutical ingredients (APIs), which call for sophisticated lipid-based excipients and carriers to increase solubility, bioavailability, and targeted administration.
The lipid-based pharma excipients market is expanding significantly as a result of the growing need for improved medication administration, bioavailability, and solubility. A variety of drug delivery systems, including liposomes, lipid nanoparticles, and self-emulsifying drug delivery systems (SEDDS), depend heavily on lipid-based excipients, such as phospholipids, fatty acids, triglycerides, and sterols. Furthermore, the lipid-based pharma excipients market grew steadily due to improvements in drug delivery methods and the growing use of lipid-based formulations in topical, injectable, and enteral medicinal products. Additionally, the lipid-based pharma excipients market is controlled by large companies that prioritize alliances, innovation, and growth tactics. To improve their medication delivery capabilities, corporations are increasingly purchasing smaller businesses with experience in lipid nanoparticle technology.
In addition, the patent expirations for major pharmaceutical medications have also contributed to the growing need for lipid-based pharma excipients by raising competition and lowering drug prices. This has further increased the need for cost-effective excipients. The developments in formulation technology and artificial intelligence (AI) have boosted the lipid-based pharma excipients market growth. Lipid-based formulations can be developed more quickly by incorporating AI-driven modeling, which will improve predictability and shorten time-to-market. Furthermore, the potential for successful lipid-based formulations has been further enhanced by the development of new excipients and formulation methods. Moreover, because of the possibility of interactions between lipid-based pharma excipients and the active ingredient, biological environments, and container closure mechanisms, regulatory authorities have modified rules in response to new knowledge. These factors are anticipated to boost the lipid-based pharma excipients market expansion over the forecast period.
• ABF Ingredients - ABITEC
• Gattefosé
• AAK
• CREMER OLEO
• IOI Oleo GMbH
• Merck KGaA
• BASF
• Croda International
• Alsiano
• Evonik
• Kao Corporation
• Biopharma PEG Scientific
• CD Formulation
• CordenPharma
• Lipoid
• NOF CORPORATION
• CLARIANT
• Colorcon
The lipid-based pharma excipients market is anticipated to develop in the future due to the increase in gene therapy. The advances in delivery technologies have made it possible to introduce genetic material into cells in a safe, effective, and focused manner, which has led to an increase in gene therapy. Lipid-based pharma excipients improve gene therapy by facilitating effective delivery systems, guaranteeing genetic material integrity, and facilitating targeted transport. By safeguarding nucleic acids and promoting cellular uptake, they enhance therapeutic results and increase the efficacy of contemporary treatments. For instance, the Food and Drug Administration (FDA) approved six gene therapy products in 2023, up from five in 2022, according to the American Society of Gene & Cell Therapy (ASGCT), a non-profit medical and scientific organization based in the United States. Consequently, the lipid-based pharma excipients market is expanding due to the surge in gene therapy.
The complexity of formulation creation and stability control is one of the main obstacles in the lipid-based pharmaceutical excipients market. To guarantee appropriate drug solubility and reliable performance, lipid-based systems require careful selection of lipid types, surfactants, and cosolvents. These compositions' stability and shelf life may be impacted by environmental elements like temperature, oxidation, and moisture. Additionally, the large-scale manufacturing also poses technological difficulties in maintaining uniformity, which raises development time and production costs. In order to comply with regulations, pharmaceutical businesses must also carry out comprehensive compatibility and stability tests. These technical issues might hinder the development of new products and restrict the use of lipid-based excipients, especially for businesses with little manufacturing or formulation experience.
The oils category held the largest share in the Lipid-based Pharma Excipients market in 2025 driven by growing demand in the industrial, personal care, and pharmaceutical industries. The acceptance of nutraceuticals, improvements in lipid-based medication delivery, and a move toward sustainable components are the main causes of this growth. Refined vegetable oils, or PURECO oils from ABITEC, are essential for melting and lubricating a variety of products, including fiberglass and pharmaceuticals. Additionally, vegetable oils, medium-chain triglycerides, and long-chain triglycerides are frequently utilized in lipid-based drug delivery systems, such as soft gelatin capsules and self-emulsifying drug delivery systems. These oils aid in the dissolution of lipophilic active medicinal substances and promote better gastrointestinal absorption. Furthermore, the oil-based excipients category is being driven by the growing number of medication candidates in the pharmaceutical pipeline that have limited water solubility.
In 2025, the pharma & biotech companies category dominated the Lipid-based Pharma Excipients market. Lipid excipients have gained popularity in pharmaceutical manufacturing and are now mostly utilized to improve the solubility of active compounds. Lipophilic active substances that would otherwise be poorly water-soluble can have their bioavailability increased by using lipid-based formulations. For oral formulations in pharmaceutical manufacturing, these elements are crucial. The greatest demand for lipid-based excipients is driven by pharmaceutical and biotech businesses because of their expanding production capacity, growing competition for market share, desire to provide the best goods, and ability to maintain the highest volume and revenue in the sector. Additionally, the lipid-based pharma excipients market is growing due in large part to investments in research and development, especially in the pharmaceutical end-use sector. As the industry continues to change, this trend is anticipated to continue.
The Lipid-based Pharma Excipients market was dominated by North America region in 2025. North America has a robust market environment that is well-represented in both huge industrial heavyweights and innovative entrepreneurs. For instance, Evonik formally started building its USD 220 million worldwide pharmaceutical specialty lipid production facility in Lafayette, Indiana, in April 2023. The region's sophisticated pharmaceutical manufacturing infrastructure, robust R&D base, and top international drug manufacturers have fueled the lipid-based pharma excipients market. Additionally, the market is being promoted by the growing tendency towards more individualized treatments, which is impacting the demand for customized excipient solutions. Because of the growing frequency of chronic diseases and the use of personalized medicine, the United States is dominating the North American lipid-based pharma excipients market over the forecast period.
| Report Attribute | Specifications |
| Market size value in 2025 | USD 1.03 Bn |
| Revenue forecast in 2035 | USD 1.96 Bn |
| Growth Rate CAGR | CAGR of 7.0% from 2026 to 2035 |
| Quantitative Units | Representation of revenue in US$ Bn and CAGR from 2026 to 2035 |
| Historic Year | 2022 to 2025 |
| Forecast Year | 2026-2035 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | Product Type, Formulation, Functionality, End-user, and By Region |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; Southeast Asia |
| Competitive Landscape | ABF Ingredients – ABITEC, Gattefosé, AAK, CREMER OLEO, IOI Oleo GMbH, Merck KGaA, BASF, Croda International, Alsiano, Evonik, Kao Corporation, Biopharma PEG Scientific, CD Formulation, CordenPharma, Lipoid, NOF CORPORATION, CLARIANT, and Colorcon |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Geographic competitive landscape. |
| Pricing and Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
• Fats
• Oils
• Phospholipids
• Waxes
• Others
• Injectables
• Enteral
• Topical
• Solubilizers & Wetting Agents
• Penetration Enhancers & Solvents
• Structuring Agents & Lubricants
• Emollients
• Emulsifiers & Surfactants
• Others
• Pharma & Biotech Companies
• Contract Research Organizations (CROs) & Contract Development and Manufacturing Organizations (CDMOs)
• Contract Manufacturing Organizations (CMOs)
• Academic & Research Institutes
North America-
• The US
• Canada
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Mexico
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.